Developing a Clinico-Molecular Test for Individualized Treatment of Ovarian Cancer: The interplay of Precision Medicine Informatics with Clinical and Health Economics Dimensions

AMIA Annu Symp Proc. 2018 Dec 5:2018:1093-1102. eCollection 2018.

Abstract

We report recent progress in the development of a precision test for individualized use of the VEGF-A targeting drug bevacizumab for treating ovarian cancer. We discuss the discovery model stage (i.e., past feasibility modeling and before conversion to the production test). Main results: (a) Informatics modeling plays a critical role in supporting driving clinical and health economic requirements. (b) The novel computational models support the creation of a precision test with sufficient predictivity to reduce healthcare system costs up to $30 billion over 10 years, and make the use of bevacizumab affordable without loss of length or quality of life.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents, Immunological / therapeutic use*
  • Bevacizumab / therapeutic use*
  • Carcinoma, Ovarian Epithelial / drug therapy*
  • Computational Biology*
  • Computer Simulation
  • Cost Savings
  • Data Science
  • Delivery of Health Care / economics
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Models, Biological
  • Molecular Targeted Therapy* / economics
  • Ovarian Neoplasms / drug therapy*
  • Precision Medicine / methods*
  • Quality of Life
  • Therapy, Computer-Assisted*

Substances

  • Antineoplastic Agents, Immunological
  • Bevacizumab